Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | FAP | Q12884 | 5/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5719224 | 0.94 | DPP4 (0.67) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5719403 | 0.91 | DPP4 (0.77) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5718795 | 0.88 | DPP4 (0.73) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5719225 | 0.88 | DPP4 (0.73) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5719250 | 0.86 | DPP4 (0.83) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5275960 | 0.86 | DPP4 (1.00) | DPP4L3MBTL1FAPDPP9 | |
| Trifluoroacetic Acid SCHEMBL6689940 | 0.86 | DPP4 (0.69) | DPP4L3MBTL1FAPDPP9 | |
| SCHEMBL5719078 | 0.85 | DPP4 (0.82) | DPP4L3MBTL1FAPDPP9 | |
| Trifluoroacetic Acid SCHEMBL5718973 | 0.85 | DPP4 (0.74) | DPP4L3MBTL1FAPDPP9 | |
| Trifluoroacetic Acid SCHEMBL5719098 | 0.84 | DPP4 (0.66) | DPP4L3MBTL1FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | claimed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | claimed |
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | DPP4 1/4885L3MBTL1 1200/4885FAP 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.